Related Experiment Video
Updated: Jun 12, 2026
09:33
Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Formaldehyde, Epigenetics, and Alzheimer's Disease
Fei Wang1, Danqi Chen, Peipei Wu
1School of Public Health , China Medical University , Shenyang 110122 , China.
Chemical Research in Toxicology
|April 10, 2019
Summary
Formaldehyde (FA), an environmental pollutant and endogenous metabolite, may contribute to Alzheimer's disease (AD) by inhibiting histone acetylation and compromising chromatin assembly, a process linked to aging and AD progression.
Area of Science:
- Neuroscience
- Epigenetics
- Environmental Health
Background:
- Alzheimer's disease (AD) is a leading cause of dementia, characterized by beta-amyloid plaques and tau tangles.
- Most clinical trials targeting beta-amyloid have failed, prompting a re-evaluation of AD pathogenesis and therapeutic strategies.
- Complex interactions of genetic, epigenetic, and environmental factors contribute to AD development.
Purpose of the Study:
- To review mechanistic insights into Alzheimer's disease (AD), focusing on epigenetic alterations.
- To explore the role of formaldehyde (FA) exposure in AD pathogenesis.
- To identify potential novel therapeutic targets by investigating chemical exposures in AD.
Main Methods:
- Review of current literature on AD mechanisms, epigenetic alterations, and formaldehyde's role.
- Analysis of studies demonstrating formaldehyde's impact on histone acetylation and chromatin assembly.
- Examination of the link between formaldehyde-induced epigenetic changes, aging, and AD.
Main Results:
- Formaldehyde (FA) reduces lysine acetylation of cytosolic histones, impairing chromatin assembly.
- This process leads to a loss of histone content in chromatin, a hallmark of aging.
- FA-induced epigenetic alterations may contribute to the initiation and progression of Alzheimer's disease.
Conclusions:
- Formaldehyde exposure is implicated in Alzheimer's disease development through epigenetic modifications.
- Understanding the role of environmental factors like formaldehyde offers new perspectives on AD mechanisms.
- Investigating chemical exposures may reveal novel therapeutic targets for Alzheimer's disease.
More Related Videos
13:47Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
Published on: March 29, 2019
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...